The results of the current study identified seven target genes of dehydrovomifoliol in NAFLD treatment, namely E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA. This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatotic liver disease.